A detailed history of Oppenheimer Asset Management Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Oppenheimer Asset Management Inc. holds 152,076 shares of GILD stock, worth $10.4 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
152,076
Previous 177,387 14.27%
Holding current value
$10.4 Million
Previous $14.4 Million 22.48%
% of portfolio
0.17%
Previous 0.2%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

SELL
$71.58 - $87.29 $1.81 Million - $2.21 Million
-25,311 Reduced 14.27%
152,076 $11.1 Million
Q4 2023

Feb 13, 2024

BUY
$73.27 - $83.09 $351,842 - $398,998
4,802 Added 2.78%
177,387 $14.4 Million
Q3 2023

Nov 07, 2023

BUY
$73.94 - $80.67 $428,704 - $467,724
5,798 Added 3.48%
172,585 $12.9 Million
Q2 2023

Aug 02, 2023

SELL
$76.01 - $86.7 $1.12 Million - $1.28 Million
-14,764 Reduced 8.13%
166,787 $12.9 Million
Q1 2023

May 10, 2023

BUY
$77.31 - $88.08 $52,184 - $59,454
675 Added 0.37%
181,551 $15.1 Million
Q4 2022

Feb 06, 2023

BUY
$62.32 - $89.47 $156,485 - $224,659
2,511 Added 1.41%
180,876 $15.5 Million
Q3 2022

Nov 14, 2022

BUY
$59.54 - $68.01 $2.09 Million - $2.38 Million
35,046 Added 24.45%
178,365 $11 Million
Q2 2022

Aug 08, 2022

BUY
$57.72 - $65.01 $36,248 - $40,826
628 Added 0.44%
143,319 $8.86 Million
Q1 2022

May 12, 2022

BUY
$57.92 - $72.58 $325,104 - $407,391
5,613 Added 4.09%
142,691 $8.48 Million
Q4 2021

Feb 02, 2022

BUY
$64.88 - $73.64 $2.1 Million - $2.38 Million
32,381 Added 30.93%
137,078 $9.95 Million
Q3 2021

Nov 12, 2021

BUY
$67.69 - $73.03 $45,149 - $48,711
667 Added 0.64%
104,697 $7.31 Million
Q2 2021

Aug 03, 2021

BUY
$63.47 - $69.35 $2.38 Million - $2.6 Million
37,488 Added 56.34%
104,030 $7.16 Million
Q1 2021

May 17, 2021

BUY
$60.0 - $68.46 $203,520 - $232,216
3,392 Added 5.37%
66,542 $4.3 Million
Q4 2020

Feb 11, 2021

SELL
$56.65 - $64.55 $57,103 - $65,066
-1,008 Reduced 1.57%
63,150 $3.68 Million
Q3 2020

Nov 13, 2020

SELL
$62.1 - $78.08 $702,413 - $883,162
-11,311 Reduced 14.99%
64,158 $4.06 Million
Q2 2020

Aug 11, 2020

BUY
$72.34 - $84.0 $35,012 - $40,656
484 Added 0.65%
75,469 $5.81 Million
Q1 2020

May 08, 2020

BUY
$62.63 - $80.22 $2.95 Million - $3.78 Million
47,164 Added 169.53%
74,985 $5.61 Million
Q4 2019

Feb 07, 2020

SELL
$61.62 - $67.78 $91,505 - $100,653
-1,485 Reduced 5.07%
27,821 $1.81 Million
Q3 2019

Oct 31, 2019

BUY
$62.51 - $69.0 $1.28 Million - $1.41 Million
20,425 Added 229.99%
29,306 $1.86 Million
Q2 2019

Aug 09, 2019

BUY
$61.87 - $69.38 $17,880 - $20,050
289 Added 3.36%
8,881 $599,000
Q1 2019

Apr 24, 2019

SELL
$62.53 - $70.05 $613,419 - $687,190
-9,810 Reduced 53.31%
8,592 $559,000
Q4 2018

Jan 30, 2019

SELL
$60.54 - $79.0 $100,012 - $130,508
-1,652 Reduced 8.24%
18,402 $1.15 Million
Q3 2018

Oct 26, 2018

BUY
$71.28 - $78.92 $791,208 - $876,012
11,100 Added 123.97%
20,054 $1.55 Million
Q2 2018

Aug 10, 2018

BUY
$64.88 - $75.68 $28,806 - $33,601
444 Added 5.22%
8,954 $634,000
Q1 2018

May 09, 2018

BUY
$72.84 - $88.8 $144,296 - $175,912
1,981 Added 30.34%
8,510 $642,000
Q3 2017

Nov 14, 2017

BUY
$72.11 - $85.47 $470,806 - $558,033
6,529
6,529 $530,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $85.7B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Oppenheimer Asset Management Inc. Portfolio

Follow Oppenheimer Asset Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.